{name}
{subtitle}
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
city
~51 mi. (Floreşti, Romania, +158 more cities)
facility
S.C. Radiotherapy Center Cluj S.R.L ( Site 2503)
drug
olaparib, +4 more drugs
drug type
chemotherapy, +3 more types
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
city
~51 mi. (Floreşti, Romania, +105 more cities)
facility
SC Radiotherapy Center Cluj SRL ( Site 1105)
biomarker
ATM Loss, +62 more biomarkers
condition
Breast Carcinoma, +2 more conditions
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~58 mi. (Cluj-Napoca, Romania, +137 more cities)
facility
Spitalul Universitar CF Cluj-Napoca ( Site 1103), +1 more facility
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
city
~58 mi. (Cluj-Napoca, Romania, +126 more cities)
facility
Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 0392), +1 more facility
drug
FOLFOX regimen, +3 more drugs
drug type
chemotherapy, +2 more types
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
city
~58 mi. (Cluj-Napoca, Romania, +92 more cities)
facility
Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 0249)
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
city
~58 mi. (Cluj-Napoca, Romania, +115 more cities)
facility
Medisprof ( Site 1102)
biomarker
ATM Loss, +27 more biomarkers
condition
Breast Carcinoma, +2 more conditions
drug
olaparib, +1 more drug
drug type
immunotherapy, +1 more type
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~100 mi. (Gyula, Hungary, +144 more cities)
facility
Bekes Megyei Kozponti Korhaz - Pandy Kalman Tagkorhaza ( Site 2309)
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
city
~100 mi. (Gyula, Hungary, +105 more cities)
facility
Bekes Megyei Kozponti Korhaz - Pandy Kalman Tagkorhaza ( Site 1432)
drug
bevacizumab, +1 more drug